https://www.cnn.com/2021/04/18/americas/canada-hos
Post# of 148190
CYDY def not putting all their eggs in one basket anymore like last year with the US FDA. This year they have shifted focus to the countries that give CYDY the best opportunity for EUA. They happen to now be working with all the countries that need leronlimab the most. I have a sales back ground and I can tell you it’s a lot easier to sell a product that solves some sort of problem (death) and it’s even easier if it’s unique patented, best in category. Leronlimab would exceed all the main Sales criteria. The demand will soon be way larger than supply and than I could see Manufacturing as what main focus of company will be.